Search Results
Genomics of Diffuse Large B Cell Lymphoma: pervasive role of super-enhancer hypermutation in dysregulating oncogene expression
We recently identified a pervasive, pathogenically relevant mutational mechanism that targets super-enhancers (SE) in DLBCL, leading to target gene deregulation. Here we will dissect the mechanistic role of 3 highly recurrent hotspots in the BCL6, BTG2 and CXCR4 SEs in driving lymphomagenesis and tumor dependency in vitro and in vivo using novel mouse models. These studies will significantly transform our understanding of DLBCL and identify novel therapeutic targets.Brexucabtagene autoleucel
Brexucabtagene autoleucel is FDA approved for the treatment of
- Adult patients with relapsed or refractory mantle cell lymphoma (MCL).
This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. - Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Why our health equity grants are more important than ever before
For 40 years, I’ve poured my life into fighting cancer. Working alongside doctors, nurses, social workers, researchers—and of course patients and their loved ones—we’ve made incredible progress.
But what keeps me up at night after all these years is the realization that, for too long, the health sector didn’t focus on the holes in that progress. As we collectively sprinted towards better treatments, we’ve left some patients behind.
MY FIRST 100 DAYS AS LLS PRESIDENT & CEO
Dear Friends,
I’m just over 100 days into my new role as President & CEO of The Leukemia & Lymphoma Society (LLS) and I want to take this moment to say how grateful and proud I am to work alongside all of you in service of blood cancer patients and their families. It’s been great meeting many of you as I travel to our regions and meet with departments throughout the country. And I look forward to meeting many more of you in the months ahead.
Shop Online and In-Store at Walgreens to Support LLS
The Leukemia & Lymphoma Society (LLS) and Walgreens are in your corner.
Since 2019, Walgreens has helped to raise more than $30 million for LLS and Susan G. Komen, all with a clear goal in mind: to advance research for tough-to-treat cancers and increase equitable access to care.
Finding Support in Community: Walgreens and LLS Show Up for Blood Cancer Patients
We all need a helping hand sometimes.
Add on a cancer diagnosis and the everyday suddenly feels... different. In many ways, harder.
#ASH18: Beating AML
Sunday marked a significant milestone for The Leukemia & Lymphoma Society (LLS) and the patients we help. Here at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, a conference attended by more than 30,000 scientists from around the world, we unveiled the first results from our groundbreaking precision medicine Beat AML Master Clinical Trial. To date, more than 356 patients have been screened for this trial.
“Stages” of Leukemia: Understanding Classification and Progression
Table of contents
